Clinical Trials Logo

Lung Small Cell Carcinoma clinical trials

View clinical trials related to Lung Small Cell Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04701307 Active, not recruiting - Clinical trials for Stage III Lung Cancer AJCC v8

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of niraparib and dostarlimab in treating small cell lung cancer and other high-grade neuroendocrine carcinomas. Niraparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal antibodies, such as dostarlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving niraparib and dostarlimab may help to control the diseases.